An observational study in Pulmonary Embolism Acute Massive, sponsored by Supergene, LLC. Recruiting at 14 sites in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Supergene, LLC · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of FORPE Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with massive pulmonary embolism in routine clinical practice.
In November 2023 a multicenter, open-label, randomized non-inferiority trial of the efficacy and safety of the non-immunogenic staphylokinase (Fortelyzin®) compared with alteplase (Actilyse®) in patients with massive pulmonary embolism (FORPE) has been completed (NCT04688320).
FORPE trial is the first report of the non-immunogenic staphylokinase usage in patients with massive pulmonary embolism accompanied by unstable haemodynamics. Non-immunogenic staphylokinase was found to be non-inferior to alteplase (p=1.00). Non-immunogenic staphylokinase had high safety profile and did not cause the major bleeding. No cases of haemorrhagic stroke or major bleeding were recorded in the non-immunogenic staphylokinase group, whereas there were five cases (5%) of BARC type 3+5 bleedings in the alteplase group (p=0.026). All major bleedings and fatal intracranial haemorrhage in the alteplase group were registered only in 60 years old patients.
The unique mechanism of action of non-immunogenic staphylokinase allows it to be used in a single dose of 15 mg, regardless of the patient's body weight. Non-immunogenic staphylokinase is easy to administer with a rapid single bolus that makes it convenient for use in emergency medicine.
The indication "massive pulmonary embolism" is included in the Instructions for medical use of the non-immunogenic staphylokinase. In routine clinical practice, the non-immunogenic staphylokinase is used for massive pulmonary embolism treatment since 2024.
The aim of FORPE Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with massive pulmonary embolism in routine clinical practice.
833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.
This study's planned enrollment of 20,000 is above the median of 361 across 366 observational studies indexed under Pulmonary Embolism.
Browse Pulmonary Embolism studies →Supergene, LLC is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Men and women aged 18 years and older with verified massive pulmonary embolism, who received a single intravenous bolus of the non-immunogenic staphylokinase (15 mg).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Increased risk of bleeding:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: non-immunogenic staphylokinase 15 mg as a single intravenous bolus Other Names: Fortelyzin®
Drug: Non-immunogenic staphylokinasenon-immunogenic staphylokinase 15 mg as a single intravenous bolus Other Names: Fortelyzin®
Non-immunogenic staphylokinase 15 mg as a single intravenous bolus
Also known as: Fortelyzin®
All-cause mortality
The number of death from any causes during hospitalization
Time frame: day 7 after drug administration
All-cause mortality
The number of death from any causes during 30 days after drug administration
Time frame: day 30 after drug administration
Haemodynamic Collapse
The number of haemodynamic collapses from any causes during 30 days after drug administration
Time frame: day 30 after drug administration
Recurrent Pulmonary Embolism
The number of recurrent pulmonary embolism from any causes during 30 days after drug administration
Time frame: day 30 after drug administration
Pulmonary Artery Systolic Pressure Measures
The efficacy is evaluated in terms of pulmonary artery systolic pressure after drug administration
Time frame: baseline and day 2 after drug administration
Intracranial haemorrhage
The number of intracranial haemorrhage during 30 days after drug administration
Time frame: day 30 after drug administration
Major bleedings
The number of major bleedings (according to BARC classification type 3 and 5) during 30 days after drug administration
Time frame: day 30 after drug administration
Plan to share: No
Started Jun 2025 (actual). Primary completion is estimated for Oct 2027, 28 months after the start.
Of 160 observational studies under Pulmonary Embolism, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 105. This study's planned 28 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Supergene, LLC